What is the half-life of CJC-1295?

The phase 1 study estimated it at 5.8 to 8.1 days, which is unusually long for a peptide and is the point of the albumin-binding modification.

Is CJC-1295 approved?

No. It has published phase 1 human data but no FDA approval, and development did not continue to a marketed product.

How much research exists on CJC-1295?

Thirty-three PubMed records in total, of which twenty-one are tagged to human subjects and two are typed as clinical trials. That is a small literature by any standard.

CJC-1295: half-life, evidence and what trials used

CJC-1295 is a long-acting analogue of growth hormone-releasing hormone, modified to bind albumin and extend its duration of action.

Also known as CJC1295, DAC:GRF, modified GRF 1-29.

Evidence and regulatory status

In registered human trials. Not approved for this use.

Not approved by the FDA for any indication. Prohibited in sport as a growth hormone-releasing factor.

Half-life

CJC-1295 has a reported terminal half-life of about 7 days. Estimated at 5.8 to 8.1 days in the phase 1 study. Figure taken from Teichman 2006.

What published trials used

The phase 1 study administered single subcutaneous doses of 30, 60, 125 and 250 micrograms per kilogram to healthy adults.

Reported for reference only. What a trial administered under supervision is not a recommendation, and Gireta does not make one.

How much research exists

PubMed records: 33
Tagged human: 21
Clinical trials: 2

A PubMed search for CJC-1295 returns 33 records, of which 21 are tagged as human research and 2 are typed as a clinical trial.

Counted on 2026-09-04. Counts drift, so the exact query is linked rather than described, and you can re-run it.

Common questions

What is the half-life of CJC-1295?: The phase 1 study estimated it at 5.8 to 8.1 days, which is unusually long for a peptide and is the point of the albumin-binding modification.
Is CJC-1295 approved?: No. It has published phase 1 human data but no FDA approval, and development did not continue to a marketed product.
How much research exists on CJC-1295?: Thirty-three PubMed records in total, of which twenty-one are tagged to human subjects and two are typed as clinical trials. That is a small literature by any standard.

Sources

Teichman 2006 · Journal of Clinical Endocrinology and Metabolism, via PubMed, 2006

Related compounds

Growth hormone secretagogues

Prompt the pituitary to release growth hormone rather than supplying growth hormone directly.

Tesamorelin Tesamorelin is a synthetic growth hormone-releasing factor analogue approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy.
Ibutamoren Ibutamoren is an orally active ghrelin receptor agonist that raises growth hormone and IGF-1 levels.
Ipamorelin Ipamorelin is a selective growth hormone secretagogue that acts at the ghrelin receptor.

Planning a schedule?

Gireta turns a compound and a cadence into a twelve-week timeline with the reconstitution maths worked out and a monthly cost.

Plan a CJC-1295 schedule

Last reviewed 2026-09-04.